SCHEMBL7016312

SCHEMBL7016312

CCn1c(=O)n(Cc2cccc(F)c2)c(=O)c2cc(C(=O)O)ccc21

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.50
HDAC1 Q13547 3/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
POLB P06746 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
LMNA P02545 1/20 0.47
GLA P06280 1/20 0.47
THRB P10828 1/20 0.46
MMP13 P45452 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
FEN1 P39748 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6243124 0.89 MMP13 (0.55) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL7102220 0.89 POLB (0.52) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL6255189 0.88 MMP13 (0.58) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL7649381 0.84 MAPT (0.49) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL17434512 0.82 KDM4E (0.55) MAPTPOLBALDH1A1HTTSMN1; SMN2
SCHEMBL7101613 0.77 PARG (0.50) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL6518639 0.76 KDM4E (0.62) MAPTHDAC1HDAC11HDAC8HDAC6
SCHEMBL6241073 0.76 MMP13 (0.71) HDAC1HDAC11HDAC8HDAC6ALDH1A1
SCHEMBL6238935 0.75 MMP13 (0.61) HDAC1HDAC11HDAC8HDAC6NPSR1
SCHEMBL7012936 0.75 MMP13 (0.61) MAPTHDAC1HDAC6SMN1; SMN2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
CN-1537105-A Quinazolines useful as MMP-13 inhibitors ��������ʲ��������ι�˾ 2004-10-13 CN disclosed
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MAPT 4823/4885HDAC1 550/4885HDAC11 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.